Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III booster trial of WSK-V102D XBB trimer protein COVID-19 vaccine in adults
ChiCTR2300078836Phase 3Recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant COVID-19 variant vaccine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: First etiologically confirmed symptomatic COVID-19 from >14 days to 6 months after booster and Adverse events and adverse reactions from 0 to 7 days after booster. Started Dec 2023; status: recruiting.
02
Drugs
recombinant COVID-19 variant vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300078836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078836.